W
WAVEMAN · COMPANY
NRC · Nrc Health
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

NRC

NRC HEALTH
PHARMA & BIOTECH · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · CIK 0000070487
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
-4.0%
XBRL, annual
NET MARGIN
8.4%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
no Form 4 purchases or sales on file
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
-4.0% year over year
below 64% of Pharma & Biotech
MARGIN
8.4% net margin
more than 78% of Pharma & Biotech
BUYBACKS
$9.6M repurchased, FY to 2026-06-30
below 72% of Pharma & Biotech
SHORT
2.3% of shares outstanding short · 5.4 days to cover · settled 2026-07-31
below 62% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +45.9%
+45.9%12M
-24%+3%+30%+56%2025-092025-102025-122026-032026-052026-072026-09 2026-02-17 · HARRISON SHANE R bought $98.2K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
Every figure on this page is a federal filing, dated the day it became public — so you can test what was knowable, not what is known now.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for NRC HEALTH in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
HARRISON SHANE R
EVP & Chief Financial Officer
BUY
2026-02-17
8,000.0
$98.2K
Freeman Jordan Nicole
Chief Accounting Officer
BUY
2025-07-31
771.0
$10.0K
BEANS PATRICK E
BUY
2025-05-12
2,500.0
$34.0K
Common Property Trust
SELL
2024-03-01
598,653.0
$24.3M
Amandla MK Trust
SELL
2024-01-05
2,614.0
$105.1K
103 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 98 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Executive pay vs shareholder return · Mr. Green
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2024
$184.9K
-$43.5K
$1.1M
-71%
+43%
2023
$195.6K
$202.2K
$428.2K
-36%
+28%
2022
$181.2K
$184.5K
$410.1K
-40%
+10%
2021
$217.1K
$207.8K
$490.5K
-35%
+38%
2020
$254.5K
-$329.9K
$524.4K
-34%
+20%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$137.4M$143.1M$148.6M$151.6M
OPERATING INCOME$22.6M$35.2M$40.0M$46.5M
NET INCOME$11.6M$24.8M$31.0M$31.8M
EPS (DILUTED)50.001.041.251.27
OPERATING CASH FLOW$26.4M$34.6M$38.1M$36.3M
CASH$4.1M$4.2M$6.7M$25.0M
LONG-TERM DEBT$75.0M$57.9M$29.5M$22.3M
BUYBACKS$20.2M$30.9M$19.1M$27.6M
DIVIDENDS PAID$11.0M$11.5M$36.4M$21.0M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →